Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (Diluted Average) (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $797.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 7.77% to $797.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $797.1 million through Dec 2025, up 7.77% year-over-year, with the annual reading at $797.1 million for FY2025, 7.77% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $797.1 million at Mereo BioPharma, roughly flat from $796.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $797.1 million in Q4 2025, with the low at $623.9 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $725.8 million, with a median of $754.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 22.55% in 2024, then grew 3.1% in 2025.
  • Over 3 years, Shares Outstanding (Diluted Average) stood at $659.5 million in 2023, then rose by 12.16% to $739.6 million in 2024, then rose by 7.77% to $797.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $797.1 million, $796.0 million, and $794.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.